Abstract
Since the original definition of the oligometastatic state in 1995,1 the potential to cure metastatic cancer with local ablative therapy has generated substantial enthusiasm. In the intervening 25 years, local ablative therapies such as surgery, stereotactic ablative body radiotherapy (SABR), and thermal ablation have been widely adopted in some countries for patients with oligometastatic cancers. Unfortunately, supporting evidence has lagged behind this enthusiasm. Until recently, only non-randomised supporting data were available, suggesting that better than expected outcomes could be achieved with ablative treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
